UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

10 UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

Read More Share:

Mar

28 FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

Read More Share:

Mar

26 New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting

Read More Share:

Mar

07 UCB Completes Acquisition of Zogenix, Inc.

Read More Share:

Feb

04 UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

Read More Share:

Jan

21 Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

Read More Share:

Jan

19 UCB to acquire Zogenix

Read More Share:

Dec

16 Positive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis Trial

Read More Share:

Dec

10 UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis

Read More Share:

Nov

19 Positive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms

Read More Share:

Categories

Archives

May

10

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

Mar

28

FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

Mar

26

New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting

Mar

07

UCB Completes Acquisition of Zogenix, Inc.

Feb

04

UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

Jan

21

Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

Jan

19

UCB to acquire Zogenix

Dec

16

Positive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis Trial

Dec

10

UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis

Nov

19

Positive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms

Choose Country

UCB in the U.S.

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

May

10

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

Mar

28

FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

Mar

26

New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting

Mar

07

UCB Completes Acquisition of Zogenix, Inc.

Feb

04

UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

Jan

21

Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

Jan

19

UCB to acquire Zogenix

Dec

16

Positive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis Trial

Dec

10

UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis

Nov

19

Positive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms

Choose Country

UCB in the U.S.

Innovation

Disease Areas

UCB Worldwide

Sustainability

Newsroom

Contact